Amgen Inc

Amgen’s Q1 2025 earnings report exceeded expectations, with top-line growth driven by key drugs, including biosimilar Stelara, solidifying the company’s momentum in the biotech space.

Amgen’s stock has surged as the biotech giant invests $200 million in a new technology center in India, signaling a renewed focus on growth and innovation.

Amgen’s recent announcement and strong quarterly earnings have sparked investor enthusiasm, solidifying its position as a market leader and fueling optimism about its future prospects.

Amgen’s stock price sees mixed trends due to a clinical hold on its obesity treatment candidate, but the company remains optimistic about its future prospects and forecasts revenue growth in 2025.